Supplementary Figure 10 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Predicting survival outcomes using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a tumor-informed bespoke approach across the trial cohort. At both baseline and cycle 3, patients were split into above- or below-median groups. Survival outcomes are shown, with hazard ratios and p-values adjusted for cohort using a Cox model. PFS analysis at cycle 3 excludes one patient who progressed before the collection of cycle 3 sample.